Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | GRK2 | P25098 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL922011 | 0.87 | CA2 (0.48) | ROCK1MAPT | |
| SCHEMBL923760 | 0.86 | TNNI3K (0.49) | TNNI3K | |
| SCHEMBL922149 | 0.83 | TNNI3K (0.43) | ROCK1TNNI3KMAPTATMKDM4E | |
| SCHEMBL923183 | 0.82 | CA2 (0.42) | MAPTATMKDM4EALDH1A1LMNA | |
| SCHEMBL923317 | 0.82 | EIF2AK2 (0.40) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL922243 | 0.80 | ALDH1A1 (0.39) | MAPTATMKDM4EMEN1ALDH1A1 | |
| SCHEMBL5669542 | 0.79 | AURKA (0.48) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL922062 | 0.79 | ALDH1A1 (0.46) | MAPTATMKDM4EMEN1ALDH1A1 | |
| SCHEMBL922039 | 0.78 | CYP2C19 (0.48) | ROCK1MAPTATMKDM4EMEN1 | |
| SCHEMBL923511 | 0.78 | CA2 (0.41) | ROCK1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | claimed |
| US-7105503-B2 | Pyrazole compounds | QLT INC. (CA) | 2006-09-12 | — | — | US | claimed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | claimed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | claimed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | claimed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7105503-B2 | Pyrazole compounds | QLT INC. (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | ROCK1 1173/4885TNNI3K 789/4885MAPT 4573/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | ROCK1 1173/4885TNNI3K 789/4885MAPT 4573/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | ROCK1 1146/4885TNNI3K 826/4885MAPT 4000/4885 |
| US-20030060453-A1 | Pyrazole compounds | CCNC, MKI67, CDC25C | ROCK1 1105/4885TNNI3K 1064/4885MAPT 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.